Clinical Trials Logo

Bone Marrow Transplant Failure clinical trials

View clinical trials related to Bone Marrow Transplant Failure.

Filter by:
  • None
  • Page 1

NCT ID: NCT03188601 Completed - GVHD Clinical Trials

α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD

AATGVHD-MARK
Start date: January 27, 2018
Phase:
Study type: Observational [Patient Registry]

Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT) levels and functions before hematopoietic stem cell transplantation and throughout progression into GVHD. PRIMARY ENDPOINT 1. Serum AAT levels and activity, before myeloablative preconditioning, as well as on days (-3),0,7,14,28 from HSCT and every 21 days thereafter. SECONDARY ENDPOINTS 1. Correlation between AAT patterns and: - Circulating immune cell activation profiles on day of ablation, 28 days from HSCT and once GVHD is diagnosed. - Patient survival - Liver function tests - GVHD grade: skin manifestations, weight, GI and liver histopathology - Graft-versus-leukemia effect

NCT ID: NCT01392989 Completed - Anemia Clinical Trials

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Start date: March 2011
Phase: Phase 2
Study type: Interventional

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

NCT ID: NCT01155817 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Start date: August 2010
Phase: Phase 1
Study type: Interventional

PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

NCT ID: NCT01135849 Completed - Breast Cancer Clinical Trials

B-Receptor Signaling in Cardiomyopathy

Start date: November 2008
Phase: N/A
Study type: Observational

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

NCT ID: NCT00896493 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Start date: May 2009
Phase: Phase 2
Study type: Interventional

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary syndrome (MF/SS).